Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Humacyte, Inc. HUMA
$3.92
-$0.3 (-7.66%)
На 18:04, 12 мая 2023
+14.80%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
459927712.00000000
-
week52high
6.38
-
week52low
1.96
-
Revenue
0
-
P/E TTM
7
-
Beta
1.21232300
-
EPS
-0.14000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BTIG | Buy | Buy | 18 июл 2022 г. |
| Cowen & Co. | Outperform | 29 окт 2021 г. | |
| Oppenheimer | Outperform | 24 сент 2021 г. | |
| BTIG | Buy | 22 сент 2021 г. | |
| Piper Sandler | Overweight | 16 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Sander Dale A. | A | 20600 | 20000 | 16 дек 2022 г. |
| Niklason Laura E | D | 17990736 | 239538 | 16 дек 2022 г. |
| Ayabudge LLC | D | 17990736 | 239538 | 16 дек 2022 г. |
| Dougan Brady W | D | 17990736 | 239538 | 16 дек 2022 г. |
| Niklason Laura E | A | 1170240 | 10000 | 15 дек 2022 г. |
| Dougan Brady W | A | 1170240 | 10000 | 15 дек 2022 г. |
| Dougan Brady W | D | 18230274 | 93426 | 15 дек 2022 г. |
| Niklason Laura E | D | 18230274 | 93426 | 15 дек 2022 г. |
| Ayabudge LLC | D | 18230274 | 93426 | 15 дек 2022 г. |
| Dougan Brady W | D | 18323700 | 276304 | 14 дек 2022 г. |
Новостная лента
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
GlobeNewsWire
23 ноя 2022 г. в 08:00
DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference taking place at the Lotte New York Palace in New York, NY, on Thursday, December 1, 2022 at 12 PM ET.
Humacyte, Inc. (HUMA) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 10:23
Humacyte, Inc. (NASDAQ:HUMA ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Conference Call Participants Eric Anderson - Cowen Suraj Kalia - Oppenheimer Bruce Jackson - The Benchmark Company Ryan Zimmerman - BTIG Operator Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2022 Results Conference Call. Currently, all participants are in a listen-only mode.
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 09:47
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
GlobeNewsWire
03 ноя 2022 г. в 08:00
DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex tissue systems, and organs at commercial scale, will release its financial results for the third quarter ended September 30, 2022, on Thursday, November 10, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
Humacyte: Intriguing Potential
Seeking Alpha
13 окт 2022 г. в 10:05
Shares of tissue regeneration firm Humacyte, Inc. are down over 70% from their opening trade post-SPAC merger in August 2021, dogged by a lack of news and slow trial enrollments. Those dynamics should change as Phase 3 data from its human acellular vessel candidate in the treatment of trauma should be forthcoming near YE22.